NIKKEI 225
27,543.39 -142.08 (-0.51%) HANG SENG
21,285.50 -13.20 (-0.06%) CRUDE OIL
77.28 +0.14 (+0.18%) GOLD FUTURES
1,889.30 +4.50 (+0.24%) DOW
34,156.69 +265.67 (+0.78%) BTC-GBP
19,296.30 +237.35 (+1.25%)
Novozymes A/S (0Q4U.IL)
| Previous close | 361.85 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 214,426 |
| Market cap | 101.095B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 27.40 |
| EPS (TTM) | 13.19 |
| Earnings date | N/A |
| Forward dividend & yield | 6.00 (1.66%) |
| Ex-dividend date | 03 Mar 2023 |
| 1y target est | 411.63 |
- Globe Newswire
Invitation to Novozymes' annual shareholders' meeting 2023
To the shareholders of Novozymes A/S The Board of Directors is pleased to invite you to the company's annual shareholders' meeting on Thursday March 2, 2023 at 4:00 pm CET at Ballerup Super Arena Please read the invitation in PDF Til Novozymes A/S' aktionærer Betyrelsen har hermed fornøjelsen af at invitere dig til selskabets ordinære generalforsamling torsdag den 2. marts 2023 kl. 16.00 i Ballerup Super Arena Læs venligst den fulde invitation i PDF format Attachments Invitation to Novozymes' An
- Globe Newswire
Novozymes delivers historically strong full-year results
Novozymes is delivering strong growth and earnings in a volatile market environment with 9% organic sales growth in 2022. This marks the highest organic sales growth in more than a decade, and Novozymes is confident about the 2023 outlook of 4-7%. COPENHAGEN, Denmark – January 26, 2026. In the 2022 financial year, Novozymes delivers 9% organic sales growth – 11% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 26.4%, and ROIC including goodwill before
